Hyaluronic Acid-FGF2-Derived Peptide Bioconjugates for Suppression of FGFR2 and AR Simultaneously as an Acne Antagonist

    February 2023 in “Journal of nanobiotechnology
    Zijian Su, Hongjie Zhang, Jieqiong Cao, Yuanmeng Sun, Yuling Cai, Bihui Zhang, He Liu, Zilei Zhang, Jianwen Xie, Qilin Meng, Lin Luo, Fu Li, Jingsheng Li, Jin‐Ting Zhang, Xiaojia Chen, Hongyu An
    TLDR The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
    The document presents a study on a novel anti-acne treatment using a bioconjugate nanoparticle named HA-P5, which is a combination of hyaluronic acid (HA) and a peptide derived from fibroblast growth factors 2 (FGF2). HA-P5 was found to suppress both fibroblast growth factor receptor 2 (FGFR2) and androgen receptor (AR) signalling, which are implicated in acne development. The treatment was effective in reducing acne lesions and sebum production both in vivo and in vitro. HA-P5 also avoids the overexpression of AKR1C3, an enzyme that can interfere with acne treatment by promoting testosterone synthesis, which is a significant advantage over the commercial FGFR inhibitor AZD4547. The study highlights the role of YTHDF3, a molecule involved in AR translation, in the signalling pathway between FGFR2 and AR. The findings suggest that HA-P5 could be a promising new treatment for acne with a dual mechanism of action on FGFR2 and AR signalling pathways.
    View this study on jnanobiotechnology.biomedcentral.com →

    Cited in this study